» Articles » PMID: 39459371

Vulvovaginal Atrophy Following Treatment for Oncogynecologic Pathologies: Etiology, Epidemiology, Diagnosis, and Treatment Options

Overview
Publisher MDPI
Specialty General Medicine
Date 2024 Oct 26
PMID 39459371
Authors
Affiliations
Soon will be listed here.
Abstract

Vulvovaginal atrophy, characterized by the thinning of vaginal mucosa typically resulting from reduced estrogen levels, is frequently exacerbated by oncogynecologic treatments such as chemotherapy, hormonal therapy, radiotherapy, or surgery. This condition significantly impacts the quality of life for cancer survivors, leading to persistent discomfort, heightened infection risk, and negative effects on sexual function and self-esteem. Despite being a relatively common complication, vulvovaginal atrophy is not always discussed before the start of treatment. Treatments typically mirror those used for natural menopause; however, efficacy and safety data specific to this population are limited due to the exclusion of these patients from clinical trials. A major safety concern is the risk of hormone-sensitive cancer recurrence associated with estrogen therapy, which drives a preference for non-hormonal alternatives. Newer treatments, such as laser therapy, radiofrequency, and vaginal injections, show promise with minimal side effects and hormone-independent mechanisms, though efficacy data varies, highlighting the need for further research. This narrative review explores the epidemiology, risk factors, diagnosis, and management of vulvovaginal atrophy after the treatment for oncogynecologic disorders.

References
1.
Quick A, Dockter T, Le-Rademacher J, Salani R, Hudson C, Hundley A . Pilot study of fractional CO laser therapy for genitourinary syndrome of menopause in gynecologic cancer survivors. Maturitas. 2020; 144:37-44. PMC: 7773136. DOI: 10.1016/j.maturitas.2020.10.018. View

2.
Hofsjo A, Bergmark K, Blomgren B, Jahren H, Bohm-Starke N . Radiotherapy for cervical cancer - impact on the vaginal epithelium and sexual function. Acta Oncol. 2017; 57(3):338-345. DOI: 10.1080/0284186X.2017.1400684. View

3.
Goldstein I, Simon J, Kaunitz A, Altomare C, Yoshida Y, Zhu J . Effects of ospemifene on genitourinary health assessed by prospective vulvar-vestibular photography and vaginal/vulvar health indices. Menopause. 2019; 26(9):994-1001. PMC: 6738630. DOI: 10.1097/GME.0000000000001350. View

4.
Cagnacci A, Xholli A, Sclauzero M, Venier M, Palma F, Gambacciani M . Vaginal atrophy across the menopausal age: results from the ANGEL study. Climacteric. 2019; 22(1):85-89. DOI: 10.1080/13697137.2018.1529748. View

5.
Stahl J, Qian J, Tien C, Carlson D, Chen Z, Ratner E . Extended duration of dilator use beyond 1 year may reduce vaginal stenosis after intravaginal high-dose-rate brachytherapy. Support Care Cancer. 2018; 27(4):1425-1433. DOI: 10.1007/s00520-018-4441-5. View